Author Correction: Angiotensin-converting enzyme 2 prevents lipopolysaccharide-induced rat acute lung injury via suppressing the ERK1/2 and NF-κB signaling pathways (Scientific Reports, (2016), 6, 1, (27911), 10.1038/srep27911);Angiotensin-converting enzyme 2 prevents lipopolysaccharide-induced rat acute lung injury via suppressing the ERK1/2 and NF-κB signaling pathways

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Li, Yingchuan ^a   Zeng, Zhen ^a   Cao, Yongmei ^a   Liu, Yujing ^a   Ping, Feng ^a   Liang, Mengfan ^a   Xue, Ying ^a   Xi, Caihua ^a   Zhou, Ming ^a   Jiang, Wei ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2-(1-CARBOXY-2-(3-(3,5-DICHLOROBENZYL)-3H-IMIDAZOL-4-YL)ETHYLAMINO)-4-METHYLPENTANOIC ACID; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN II; DIPEPTIDYL CARBOXYPEPTIDASE; G PROTEIN COUPLED RECEPTOR; IMIDAZOLE DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEUCINE; LIPOPOLYSACCHARIDE; ONCOPROTEIN; PROTO-ONCOGENE PROTEINS C-MAS-1;

ACUTE LUNG INJURY; ANALOGS AND DERIVATIVES; ANIMAL; CHEMICALLY INDUCED; DRUG EFFECT; GENE EXPRESSION REGULATION; GENE KNOCKDOWN; GENETICS; LENTIVIRUS; LUNG; MALE; MAPK SIGNALING; METABOLISM; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT;

ACUTE LUNG INJURY; ANGIOTENSIN II; ANIMALS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE KNOCKDOWN TECHNIQUES; IMIDAZOLES; LENTIVIRUS; LEUCINE; LIPOPOLYSACCHARIDES; LUNG; MALE; MAP KINASE SIGNALING SYSTEM; NF-KAPPA B; PEPTIDYL-DIPEPTIDASE A; PROTO-ONCOGENE PROTEINS; RATS, SPRAGUE-DAWLEY; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 84974808153     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-021-98272-6     Document Type: Erratum

References (52)

1. Rubenfeld, G. D. et al. Incidence and Outcomes of Acute Lung Injury. N Engl J Med 353, 1685-1693 (2005).
2. Phua, J. et al. Has mortality from acute respiratory distress syndrome decreased over time? A systematic review. Am J Respir Crit Care Med 179, 220-227 (2009).
3. Matute-Bello, G. F. C. Martin TR. Animal models of acute lung injury. Am J Physiol Lung Cell Mol Physiol 295, L379-L399 (2008).
4. Katzenstein, A. L., Bloor, C. M., Leibow, A. A. Diffuse alveolar damage-the role of oxygen, shock, related factors. A review. Am J Pathol 85, 209-228 (1976).
5. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med 342, 1301-1308 (2000).
6. Wheeler, A. P., Bernard, G. R. Acute lung injury and the acute respiratory distress syndrome: a clinical review. Lancet 369, 1553-1564 (2007).
7. Tipnis, S. R. et al. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 275, 33238-33243 (2000).
8. Suzuki, Y. et al. Inflammation and angiotensin II. Int J Biochem Cell Biol 35, 881-900 (2003).
9. Li, X., Rayford, H., Uhal, B. D. Essential roles for angiotensin receptor AT1a in bleomycin-induced apoptosis and lung fibrosis in mice. Am J Pathol 163, 2523-2530 (2003).
10. Santos, R. A., Ferreira, A. J., Verano-Braga, T., Bader, M. Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin-angiotensin system. J Endocrinol 216, R1-R17 (2013).
11. Wosten-van Asperen, R. M. et al. Acute respiratory distress syndrome leads to reduced ratio of ACE/ACE2 activities and is prevented by angiotensin-(1-7) or an angiotensin II receptor antagonist. J Pathol 225, 618-627 (2011).
12. Chappell, M. C. Nonclassical renin-angiotensin system and renal function. Compr Physiol 2, 2733-2752 (2012).
13. Jia, H. P. et al. ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia. J Virol 79, 14614-14621 (2005).
14. Rey-Parra, G. J. et al. Angiotensin converting enzyme 2 abrogates bleomycin-induced lung injury. J Mol Med (Berl) 90, 637-647 (2012).
15. Imai, Y. et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 436, 112-116 (2005).
16. Treml, B. et al. Recombinant angiotensin-converting enzyme 2 improves pulmonary blood flow and oxygenation in lipopolysaccharide-induced lung injury in piglets. Crit Care Med 38, 596-601 (2010).
17. Wang, Y. et al. Adenosine 5?-monophosphate-induced hypothermia inhibits the activation of ERK1/2, JNK, p38 and NF-kappaB in endotoxemic rats. Int Immunopharmacol 23, 205-210 (2014).
18. Liu, S., Feng, G., Wang, G. L., Liu, G. J. p38MAPK inhibition attenuates LPS-induced acute lung injury involvement of NF-kappaB pathway. Eur J Pharmacol 584, 159-165 (2008).
19. Schuh, K., Pahl, A. Inhibition of the MAP kinase ERK protects from lipopolysaccharide-induced lung injury. Biochem Pharmacol 77, 1827-1834 (2009).
20. Asaduzzaman, M., Wang, Y., Thorlacius, H. Critical role of p38 mitogen-activated protein kinase signaling in septic lung injury. Crit Care Med 36, 482-488 (2008).
21. Ferreira, A. J. et al. Angiotensin-converting enzyme 2 activation protects against hypertension-induced cardiac fibrosis involving extracellular signal-regulated kinases. Exp Physiol 96, 287-294 (2011).
22. Sukumaran, V. et al. Cardioprotective effects of telmisartan against heart failure in rats induced by experimental autoimmune myocarditis through the modulation of angiotensin-converting enzyme-2/angiotensin 1-7/mas receptor axis. Int J Biol Sci 7, 1077-1092 (2011).
23. Gallaghe, P. E., F. C. Tallant EA. MAP kinase/phosphatase pathway mediates the regulation of ACE2 by angiotensin peptides. Am J Physiol Cell Physiol 295, C1169-C1174 (2008).
24. Imai, Y. et al. Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell 133, 235-249 (2008).
25. Li, Y. et al. Angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas axis prevents lipopolysaccharide-induced apoptosis of pulmonary microvascular endothelial cells by inhibiting JNK/NF-kappaB pathways. Sci Rep 5, 8209 (2015).
26. Matute-Bello, G., Frevert, C. W., Martin, T. R. Animal models of acute lung injury. Am J Physiol Lung Cell Mol Physiol 295, L379-399 (2008).
27. Hajjar, A. M., Ernst, R. K., Tsai, J. H., Wilson, C. B., Miller, S. I. Human Toll-like receptor 4 recognizes host-specific LPS modifications. Nat Immunol 3, 354-359 (2002).
28. Hagiwara, S., Iwasaka, H., Matumoto, S., Hidaka, S., Noguchi, T. Effects of an angiotensin-converting enzyme inhibitor on the inflammatory response in in vivo and in vitro models. Crit Care Med 37, 626-633 (2009).
29. Murakami, K. et al. Heparin nebulization attenuates acute lung injury in sepsis following smoke inhalation in sheep. Shock 18, 236-241 (2002).
30. Jerng, J. S. et al. Role of the renin-angiotensin system in ventilator-induced lung injury: an in vivo study in a rat model. Thorax 62, 527-535 (2007).
31. Zhang, H., Sun, G. Y. LPS induces permeability injury in lung microvascular endothelium via AT(1) receptor. Arch Biochem Biophys 441, 75-83 (2005).
32. Shen, L. et al. Losartan prevents sepsis-induced acute lung injury and decreases activation of nuclear factor kappaB and mitogenactivated protein kinases. Shock 31, 500-506 (2009).
33. Chen, L. N. et al. Dysregulated renin-angiotensin system contributes to acute lung injury caused by hind-limb ischemia-reperfusion in mice. Shock 40, 420-429 (2013).
34. Gu, H. et al. Angiotensin-converting enzyme 2 inhibits lung injury induced by respiratory syncytial virus. Sci Rep 6, 19840 (2016).
35. Yang, P. et al. Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury. Sci Rep 4, 7027 (2014).
36. Zou, Z. et al. Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infections. Nat Commun 5, 3594 (2014).
37. He, H. et al. Mesenchymal Stem Cells Overexpressing Angiotensin-Converting Enzyme 2 Rescue Lipopolysaccharide-Induced Lung Injury. Cell Transplant 24, 1699-1715 (2015).
38. Santos, R. A. et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA 100, 8258-8263 (2003).
39. Kostenis, E. et al. G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor. Circulation 111, 1806-1813 (2005).
40. Shenoy, V. et al. The angiotensin-converting enzyme 2/angiogenesis-(1-7)/Mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med 182, 1065-1072 (2010).
41. Klein, N. et al. Angiotensin-(1-7) protects from experimental acute lung injury. Crit Care Med 41, e334-343 (2013).
42. Meng, Y. et al. Angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas axis protects against lung fibrosis by inhibiting the MAPK/NF-kappaB pathway. Am J Respir Cell Mol Biol 50, 723-736 (2014).
43. Wang, Y. K. et al. Overexpression of angiotensin-converting enzyme 2 attenuates tonically active glutamatergic input to the rostral ventrolateral medulla in hypertensive rats. Am J Physiol Heart Circ Physiol 307, H182-190 (2014).
44. Xue, T., Wei, N., Xin, Z., Qingyu, X. Angiotensin-converting enzyme-2 overexpression attenuates inflammation in rat model of chronic obstructive pulmonary disease. Inhal Toxicol 26, 14-22 (2014).
45. Song, B. et al. Loss of Angiotensin-Converting Enzyme 2 Exacerbates Myocardial Injury via Activation of the CTGF-Fractalkine Signaling Pathway. Circ J 77, 2997-3006 (2013).
46. Uhal, B. D., Li, X., Xue, A., Gao, X., Abdul-Hafez, A. Regulation of alveolar epithelial cell survival by the ACE-2/angiotensin 1-7/Mas axis. Am J Physiol Lung Cell Mol Physiol 301, L269-274 (2011).
47. Hayden, M. S., Ghosh, S. Signaling to NF-kappaB. Genes Dev 18, 2195-2224 (2004).
48. Baldwin, A. S., Jr. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 14, 649-683 (1996).
49. Yunhe, F. et al. The effect of magnolol on the Toll-like receptor 4/nuclear factor kappaB signaling pathway in lipopolysaccharideinduced acute lung injury in mice. Eur J Pharmacol 689, 255-261 (2012).
50. Abraham, E. Nuclear factor-kappaB and its role in sepsis-associated organ failure. J Infect Dis 187 Suppl 2, S364-369 (2003).
51. Haschke, M. et al. Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects. Clin Pharmacokinet 52, 783-792 (2013).
52. Petty, W. J. et al. Phase I and pharmacokinetic study of angiotensin-(1-7), an endogenous antiangiogenic hormone. Clin Cancer Res 15, 7398-7404 (2009).